Status:
COMPLETED
The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Hamilton Health Sciences Corporation
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
It is hypothesized that the intranasal administration of insulin will enhance hippocampal-dependent neurocognitive performance in euthymic patients with bipolar I or II disorder. This novel initiative...
Detailed Description
Sixty verified euthymic individuals (age 18-60) with DSM-IV-TR defined Bipolar Disorder (diagnosis will be confirmed by the Mini International Neuropsychiatric Interview for the DSM-IV) will be enroll...
Eligibility Criteria
Inclusion
- Bipolar I Disorder - Euthymic
- Bipolar II Disorder - Euthymic
Exclusion
- Unstable Medical Conditions
- Currently Manic, Depressed or Mixed
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00314314
Start Date
May 1 2006
End Date
March 1 2009
Last Update
July 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8